271 related articles for article (PubMed ID: 26447531)
1. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
[TBL] [Abstract][Full Text] [Related]
2.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
3. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
4. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
[TBL] [Abstract][Full Text] [Related]
5. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
6. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
8. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Tests for Aerosol Deposition. V: Using Realistic Testing to Estimate Variations in Aerosol Properties at the Trachea.
Wei X; Hindle M; Delvadia RR; Byron PR
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):339-348. PubMed ID: 28332899
[TBL] [Abstract][Full Text] [Related]
10. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
[TBL] [Abstract][Full Text] [Related]
11. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
Milenkovic J; Alexopoulos AH; Kiparissides C
Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
13. Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
Haynes A; Geller D; Weers J; Ament B; Pavkov R; Malcolmson R; Debonnett L; Mastoridis P; Yadao A; Heuerding S
Pediatr Pulmonol; 2016 Nov; 51(11):1159-1167. PubMed ID: 27133552
[TBL] [Abstract][Full Text] [Related]
14. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
Delvadia RR; Longest PW; Hindle M; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
[TBL] [Abstract][Full Text] [Related]
15. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
Delvadia R; Hindle M; Longest PW; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
[TBL] [Abstract][Full Text] [Related]
16. Understanding the effects of inhaler resistance on particle deposition behaviour - A computational modelling study.
Cai X; Dong J; Milton-McGurk L; Lee A; Shen Z; Chan HK; Kourmatzis A; Cheng S
Comput Biol Med; 2023 Dec; 167():107673. PubMed ID: 37956626
[TBL] [Abstract][Full Text] [Related]
17. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
Olsson B; Borgström L; Lundbäck H; Svensson M
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
Yokoyama H; Ito K; Mihashi H; Shiraishi Y; Takayanagi R; Yamada Y
Biol Pharm Bull; 2016; 39(10):1576-1580. PubMed ID: 27725433
[TBL] [Abstract][Full Text] [Related]
19. Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.
Longest PW; Tian G; Khajeh-Hosseini-Dalasm N; Hindle M
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):461-481. PubMed ID: 27082824
[TBL] [Abstract][Full Text] [Related]
20. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
